What Is Calidi Biotherapeutics, Inc. (CLDI) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Calidi Biotherapeutics, Inc. is potentially undervalued at its current price of $0.12. Based on our 13-model framework, Calidi Biotherapeutics, Inc.'s intrinsic value is estimated at a composite fair value of $0.23 — representing +88.0% implied upside — with 4 out of 5 active models confirming this thesis. Model dispersion is worth noting: CUCE targets $0.49 (+308.1%), versus Bayesian DCF at $0.10 (-15.3%). This +323.5% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About CLDI?
5 of 13 models are currently active for CLDI. Of these, 4 models suggest upside while 1 model suggests overvaluation. The Bayesian DCF estimates CLDI's intrinsic value at $0.10, implying -15.3% downside from the current price. See which stocks rank higher →
How Does CLDI Rank in Biological Products, (No Diagnostic Substances)?
Among 134 Biological Products, (No Diagnostic Substances) stocks, CLDI ranks #116 by Quality of Company score. CirclFi's QOC score of 4.0/10 evaluates 32 fundamental signals. A score of 4.0 reflects mixed fundamentals.
See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →
Calidi Biotherapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.
Is CLDI a Value Trap?
CirclFi's Value Trap algorithm assigns CLDI a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
5 of 13 models are active for Calidi Biotherapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Calidi Biotherapeutics, Inc. scores 4.0 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +323.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CLDI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CLDI's 5 active models, average confidence is 17%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad